EPICS is a drug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development

Mission & Vision

EPICS’s mission is to utilize its expertise in drug discovery and development to invent novel clinical agents targeting serious unmet medical needs in oncology. 
We develop products to meet high value-added endpoints. 
We constantly balance risk and reward in determining if and when to partner our programs.

Company timeline

  • Mar 2018     EPICS Therapeutics incorporated as ULB (University of Brussels) spin-off
  • Apr 2018     €7.2M seed-fund round completed
  • Dec 2018     EPICS acquired Ogeda former assets, adding Drug Discovery and Capabilities
  • Jan 2019     €14M Series A fund round completed